The DOI matches its Crossref record.
Pseudomonas aeruginosa pneumonia
Abstract
PURPOSE OF REVIEW: Recent articles of clinical interest on Pseudomonas aeruginosa respiratory tract infections including CAP, nosocomially-acquired pneumonia, particularly in the ventilated patient, and chronic infections in cystic fibrosis patients are reviewed. RECENT FINDINGS: The growing importance of P. aeruginosa as an etiologic agent of CAP, the occurrence of CAP in previously healthy adults and its high prevalence as an etiologic agent of late VAP are stressed in recent studies. The effect of antibiotics on the recovery of bacteria in respiratory samples of patients with VAP can be marked and as early as 12 h after administration of antimicrobials certain organisms are no longer cultivable; in contrast, P. aeruginosa can still be recovered even after 48 h of adequate therapy. Type III secretory proteins are recognized as important virulent factors in P. aeruginosa. This phenotype predicts a worse outcome in patients with VAP. Fluoroquinolones have a major role in the emergence of multiply resistant P. aeruginosa in patients with VAP. Pharmacokinetic/pharmacodynamic parameters of antimicrobials with antipseudomonal activity are gaining importance as a means of optimization of antibiotic therapy. In CF, the knowledge of the pharmacokinetics and bioavailability of inhaled tobramycin and its long term beneficial effect in lung function are important developments in this area. SUMMARY: P. aeruginosa continues to be a serious problem worldwide as a cause of respiratory tract infections in selected populations. Microbiologic diagnosis remains difficult and plagued with pitfalls. The application of modern PK/PD concepts should help to optimize antibiotic therapy of this increasingly difficult to treat infection, particularly at the respiratory tract level and with an increasing prevalence of resistance to all antipseudomonal agents. Inhaled antibiotics, particularly tobramycin, are increasingly used for the prevention and treatment of P. aeruginosa infection in CF patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Talbot, G. H., Bradley, J., Edwards, J. E., Gilbert, D., Scheld, M., & Bartlett, J. G. (2006) · Clinical Infectious Diseases · doi:10.1086/499819 · Cited by 1,104
Microorganisms Resistant to Free-Living Amoebae
Greub, G., & Raoult, D. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.413-433.2004 · Cited by 1,066
Regulation of Bacterial Virulence by Csr (Rsm) Systems
Vakulskas, C. A., Potts, A. H., Babitzke, P., Ahmer, B. M. M., & Romeo, T. (2015) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00052-14 · Cited by 346
Nseir, S., Blazejewski, C., Lubret, R., Wallet, F., Courcol, R., & Durocher, A. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03420.x · Cited by 273
Allen, L., Dockrell, D. H., Pattery, T., Lee, D. G., Cornelis, P., Hellewell, P. G., & Whyte, M. K. B. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3643 · Cited by 257
Metadata
- Authors
- Garau, J., & Gomez, L.
- Venue
- Current Opinion in Infectious Diseases
- Published
- 2003-04
- Volume
- 16
- Issue
- 2
- Pages
- 135-143
- ISSN
- 0951-7375 (ISSN-L)
- OpenAlex
- W2321428848
- Cited by
- 163
- References
- 0
- FWCI
- 9.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pseudomonas aeruginosa pneumonia. https://app.cochat.ai/papers/10.1097/00001432-200304000-00010
- The paper
- Garau, J., & Gomez, L. (2003). Pseudomonas aeruginosa pneumonia. Current Opinion in Infectious Diseases. https://doi.org/10.1097/00001432-200304000-00010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.